Shares of Vectura Group PLC (LON:VEC) have earned a consensus rating of “Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is GBX 211.29 ($2.74).

A number of equities analysts recently commented on VEC shares. Peel Hunt restated a “buy” rating and set a GBX 200 ($2.59) target price on shares of Vectura Group PLC in a report on Tuesday, March 21st. N+1 Singer restated a “buy” rating and set a GBX 202 ($2.62) target price on shares of Vectura Group PLC in a report on Tuesday, March 21st. Investec restated a “buy” rating and set a GBX 220 ($2.85) target price on shares of Vectura Group PLC in a report on Tuesday, March 21st. Stifel Nicolaus restated a “buy” rating and set a GBX 225 ($2.91) target price on shares of Vectura Group PLC in a report on Tuesday, March 21st. Finally, Numis Securities Ltd restated a “buy” rating and set a GBX 225 ($2.91) target price on shares of Vectura Group PLC in a report on Friday, March 17th.

Vectura Group PLC (VEC) traded down 0.89% during mid-day trading on Monday, hitting GBX 110.90. The company had a trading volume of 1,354,567 shares. The company’s market capitalization is GBX 751.52 million. Vectura Group PLC has a 52-week low of GBX 110.00 and a 52-week high of GBX 166.97. The company has a 50-day moving average price of GBX 117.15 and a 200 day moving average price of GBX 137.07.

ILLEGAL ACTIVITY NOTICE: “Vectura Group PLC (VEC) Receives Average Recommendation of “Buy” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/07/03/vectura-group-plc-vec-receives-average-recommendation-of-buy-from-analysts.html.

Vectura Group PLC Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.